The precision oncology landscape is undergoing a tectonic shift from reactive diagnostic profiling toward proactive molecular interception, a transition exemplified by Roche’s definitive agreement to acquire SAGA Diagnostics. This transaction, valued at up to $595 million inclusive of substantial commercial and regulatory milestone payments, represents a critical expansion of Foundation Medicine’s monitoring capabilities. As an independent subsidiary of Roche, Foundation Medi